Van Hemelrijck Mieke, Karagiannis Sophia N, Rohrmann Sabine
Division of Cancer Studies, King's College London, Translational Oncology and Urology Research (TOUR), London, UK.
Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, St. John's Institute of Dermatology, King's College London and NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London, London, UK.
Cancer Immunol Immunother. 2017 Dec;66(12):1557-1562. doi: 10.1007/s00262-017-2048-1. Epub 2017 Aug 9.
Atopy has been investigated as a potential risk factor for prostate cancer. IgE antibodies may be major players in protective responses against tumours, through engendering antigen presentation and enhancing adaptive immune responses targeted towards a specific allergen, but potentially also against tumour-associated antigens such as prostate-specific antigen (PSA). We therefore cross-sectionally investigated associations between circulating levels of PSA and IgE in the National Health and Nutrition Examination Survey 2005-2006.
We focused on all men aged 40+ years with measurements for PSA and IgE, and no previous diagnosis of prostate cancer (n = 1312). We estimated the association between total and specific IgE concentration and levels of PSA with logistic regression models, adjusted for age, ethnicity/race, education, smoking status, body mass index (BMI), physical activity status, and history of asthma.
Both total IgE and the sum of specific IgE were inversely associated with the risk of having PSA levels ≥10 ng/mL, though most findings were not statistically significant. The odds ratios for the second and third tertile of total IgE as compared to the first were 0.21 (95% CI 0.06-0.72) and 0.42 (0.08-2.31). The odds ratio for sum of abnormal specific IgE measurements was 0.77 (0.44-1.34).
Despite statistical insignificance, the observed trend warrants further research given the increasing evidence of the role of atopy and IgE antibodies in protective responses against tumours. A lifecourse approach of measuring IgE, specific subtypes, and other markers of the humoral immune system (i.e. IgG) could shed more light on its potential anti-cancer characteristics.
特应性已被作为前列腺癌的一个潜在风险因素进行研究。免疫球蛋白E（IgE）抗体可能是抗肿瘤保护性反应的主要参与者，其通过产生抗原呈递和增强针对特定过敏原的适应性免疫反应，而且潜在地也针对肿瘤相关抗原如前列腺特异性抗原（PSA）。因此，我们在2005 - 2006年美国国家健康与营养检查调查中对PSA和IgE的循环水平之间的关联进行了横断面研究。
我们关注所有年龄在40岁及以上、有PSA和IgE测量值且既往无前列腺癌诊断的男性（n = 1312）。我们用逻辑回归模型估计总IgE和特异性IgE浓度与PSA水平之间的关联，并对年龄、种族/民族、教育程度、吸烟状况、体重指数（BMI）、身体活动状况和哮喘病史进行了校正。
总IgE和特异性IgE总和均与PSA水平≥10 ng/mL的风险呈负相关，尽管大多数结果无统计学意义。总IgE第二和第三三分位数与第一三分位数相比的优势比分别为0.21（95%CI 0.06 - 0.72）和0.42（0.08 - 2.31）。异常特异性IgE测量值总和的优势比为0.77（0.44 - 1.34）。
尽管无统计学意义，但鉴于特应性和IgE抗体在抗肿瘤保护性反应中作用的证据不断增加，所观察到的趋势值得进一步研究。测量IgE、特定亚型以及体液免疫系统的其他标志物（即IgG）的生命历程方法可能会更清楚地揭示其潜在的抗癌特性。
